Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer

International Journal of Cancer

Volumn 133, Issue 11, 2013, Pages 2720-2725

  Sheng, Liming ^a,b   Luo, Min ^a,b   Sun, Xiaojiang ^a,b   Lin, Nengming ^a,b   Mao, Weimin ^a,b   Su, Dan ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology   (China)

Author keywords

nonsmall cell lung cancer; operation; prognosis; serum fibrinogen

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; SURVIVAL RATE;

NONSMALL CELL LUNG CANCER; OPERATION; PROGNOSIS; SERUM FIBRINOGEN;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBRINOGEN; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SERUM; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884903581     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28284     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-65.
3. Hirsch FR, Varella-Garcia M, Bunn PA, Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-807.
4. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-25.
5. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011; 12: 795-805.
6. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28: 744-52.
7. Kim I, Kim HG, Kim H, et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 2000; 346 Pt 3: 603-10.
8. Courtney MA, Stoler MH, Marder VJ, et al. Developmental expression of mRNAs encoding platelet proteins in rat megakaryocytes. Blood 1991; 77: 560-68.
9. Sahni A, Simpson-Haidaris PJ, Sahni SK, et al. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 2008; 6: 176-83.
10. Sahni A, Francis CW,. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000; 96: 3772-8.
11. Guadiz G, Sporn LA, Goss RA, et al. Polarized secretion of fibrinogen by lung epithelial cells. Am J Respir Cell Mol Biol 1997; 17: 60-9.
12. Molmenti EP, Ziambaras T, Perlmutter DH,. Evidence for an acute phase response in human intestinal epithelial cells. J Biol Chem 1993; 268: 14116-24.
13. Mosesson MW,. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-904.
14. Yamashita H, Kitayama J, Taguri M, et al. Effect of preoperative hyperfibrinogenemia on recurrence of colorectal cancer without a systemic inflammatory response. World J Surg 2009; 33: 1298-305.
15. Polterauer S, Seebacher V, Hefler-Frischmuth K, et al. Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol 2009; 200: 647.e1-7.
16. Polterauer S, Grimm C, Seebacher V, et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 2009; 14: 979-85.
17. Takeuchi H, Ikeuchi S, Kitagawa Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 2007; 22: 2222-7.
18. Guo Q, Zhang B, Dong X, et al. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas 2009; 38: e75-9.
19. Lu K, Zhu Y, Sheng L, et al. Serum fibrinogen level predicts the therapeutic response and prognosis in patients with locally advanced rectal cancer. Hepatogastroenterology 2011; 58: 1507-10.
20. Jones JM, McGonigle NC, McAnespie M, et al. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006; 53: 97-101.
21. Zhao J, Zhao M, Jin B, et al. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen. BMC Cancer 2012; 12: 330.
22. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
23. Vallies E, Shepherd FA, Crowley J, et al.; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4: 1049-59.
24. Blom JW, Osanto S, Rosendaal FR,. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 2: 1760-5.
25. Komurcuoglu B, Ulusoy S, Gayaf M, et al. Prognostic value of plasma D-dimer levels in lung carcinoma. Tumori 2011; 97: 743-8.
26. Unsal E, Atalay F, Atikcan S, et al. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004; 98: 93-8.
27. Gonzalez Barcala FJ, et al. Platelet count: association with prognosis in lung cancer. Med Oncol 2010; 27: 357-62.
28. Liu PL, Tsai JR, Chiu CC, et al. Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer. Mol Carcinog 2010; 49: 874-81.
29. Bobek V, Kovar J,. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004; 58: 213-9.
30. Kuderer NM, Khorana AA, Lyman GH, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110: 1149-61.
31. Zheng S, Shen J, Jiao Y, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci 2009; 100: 859-65.
32. Song N, Kuru B, Kalkan F, et al. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004; 90: 196-200.
33. Song SW, Lee HS, Kim MS, et al. Preoperative serum fibrinogen level predicts postoperative pulmonary complications after lung cancer resection. Ann Thorac Surg 2006; 81: 1974-81.